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essential role of 5-LOX metabolites in the survival of prostate cancer cells. However, downstream signaling
mechanismswhich mediate the survival-promoting effects of 5-LOXmetabolites in prostate cancer cells are still
unknown. Recently, we reported thatMK591, a speciﬁc inhibitor of 5-LOX activity, induces apoptosis in prostate
cancer cells without inhibition of Akt, or ERK, two well-characterized regulators of pro-survival mechanisms,
suggesting the existence of anAkt and ERK-independent survivalmechanism inprostate cancer cells regulatedby
5-LOX. Here, we report that 5-LOX inhibition-induced apoptosis in prostate cancer cells occurs via rapid
inactivation of protein kinase C-epsilon (PKCε), and that exogenous 5-LOX metabolites prevent both 5-LOX
inhibition-induced down-regulation of PKCε and induction of apoptosis. Interestingly, pre-treatment of prostate
cancer cells with diazoxide (a chemical activator of PKCε), or KAE1-1 (a cell-permeable, octa-peptide speciﬁc
activator of PKCε) prevents 5-LOX inhibition-induced apoptosis, which indicates that inhibition of 5-LOX triggers
apoptosis in prostate cancer cells via down-regulation of PKCε. Altogether, these ﬁndings suggest that
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Prostate cancer is themost common form ofmalignancy and second
leading cause of cancer-related deaths in men in the United States [1].
Signiﬁcant progress has been made to control localized prostate cancer
by surgery and radiation therapy. However, management of metastatic
prostate cancer still remains a major problem for which no satisfactory
measure is available. Prostate cancer initially responds to androgen-
ablation therapy, however, androgen-independent disease almost
always develops which eventually metastasizes to distant organs and
assumes a lethal phenotype [2]. No cure is currently available for
metastatic, androgen-independent prostate cancer. Lack of proper
understanding about critical molecular mechanisms in prostate cancer
cells is delaying development of effective therapeutic regimen againstprostate cancer. Thus, exploration and characterization of novel
mechanisms, that are speciﬁc and critical for prostate cancer cells, are
of utmost signiﬁcance to develop effective strategies to control this
disease.
Both epidemiological studies and experiments with laboratory
animals repeatedly suggested a link between consumption of high-fat
diets and occurrence of clinically evident prostate cancer [3–8],
indicating that dietary fatty acids and their metabolic products may
play an important role in the promotion and/or progression phases of
prostate cancer presumably via regulation of growth and survival
characteristics of prostate cancer cells. Arachidonic acid, an omega-6,
polyunsaturated fatty acid, was found to stimulate prostate cancer cell
growth via metabolic conversion through the 5-LOX pathway [9–11].
Later, it was observed that prostate cancer cells constitutively generate
5-LOX metabolites, and inhibition of 5-LOX blocks production of 5-LOX
metabolites and triggers apoptosis both in androgen-sensitive aswell as
androgen-independent prostate cancer cells [12,13]. This apoptosis is
prevented by exogenous 5(S)-HETE (5-hydroxyeicosatetraenoic acid),
and more effectively by its dehydrogenase-derivative 5-oxoETE,
suggesting a critical role of 5-LOXmetabolites in the survival of prostate
cancer cells. It is interesting to note that under normal health condition,
expression of 5-LOX is restricted to speciﬁc immune cells such as
neutrophils, eosinophils, basophils and macrophages (not in T cells)
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non-immune parenchyma body cells do not express 5-LOX unless
disease occurs, such as asthma, arthritis, psoriasis, and cancer [14–19].
Increased expression and activity of 5-LOX were observed in prostate
tumor tissues compared to adjacent non-tumor tissues [20]. Recently, it
was observed that though 5-LOX is heavily expressed in prostate tumor
tissues, its expression in normal prostate glands is undetectable
(Sarveswaran et al.; Manuscript in preparation). This ﬁnding, together
with a critical role of 5-LOX in the survival of prostate cancer cells, leads
to the concept that 5-LOX may play an important role in the
development and progression of prostate cancer. Thus, the 5-LOX
pathway is emerging as a promising target for therapeutic development
against prostate cancer. However, downstream signaling mechanisms
mediating the survival-promoting effects of 5-LOX metabolites in
prostate cancer cells are yet to be characterized.
To gain an insight into the mechanisms underlying regulation of
prostate cancer cell survival by 5-LOX activity, we systematically
addressed the involvement of, (1) the phosphatidylinositol 3′-kinase-
Akt/protein kinase B (PI3K-Akt), (2) the mitogen-activated protein
kinase kinase-extracellular signal regulated kinase (MEK-ERK), and (3)
the protein kinase C-epsilon (PKCε) pathway as potential mediator(s),
because these pathways are known to promote growth and survival of a
variety of cells including cancer cells. The PI3K-Akt axis plays an
important role in the cellular signaling network regulating various cell
functions including proliferation, apoptosis, cell growth, and metabolism
[21–25]. This pathway is over-activated inmany types of cancer cells and
is well known to contribute to cell survival through deﬁned apoptosis-
preventing mechanisms [18–20]. Because of its role in prevention of
apoptosis via multiple mechanisms, and its frequent activation in cancer
cells, the PI3K-Akt pathway is now targeted for anticancer drug
development [24,25]. Similarly, the MEK-ERK pathway is also known to
promote growth and survival of a variety of cells including cancer cells
[26–28]. Interestingly, we observed no reduction in the phosphorylation
of Akt at Ser473 or the enzymatic activity of Aktwhen prostate cancer cells
are treated with MK591 to undergo apoptosis [29]. MK591 is a widely
used speciﬁc inhibitor of 5-LOX activity, and it does not inhibit
cyclooxygenase, epoxygenase or 12-lipoxygenase activities [30,31]. We
also observed that treatment of prostate cancer cellswithMK591doesnot
inhibit the phosphorylation/activation of ERK while triggering apoptosis
in prostate cancer cells [29]. Altogether, these ﬁndings indicated that the
5-LOX inhibition-induced apoptosis in prostate cancer cell occurswithout
inhibition of Akt or ERK, and suggested the existence of an Akt- and
ERK-independent survival mechanism in prostate cancer cells regulated
by 5-LOX activity.
The initial ﬁndings of 5-LOX inhibition-induced apoptosis in
prostate cancer cells without inhibition of Akt or ERK invoked us to
examine the role of PKCε as a potential mediator of the survival-
promoting effects of 5-LOX. The PKC-family of serine-threonine
protein kinases includes about ten isoforms and are known to
regulate various cell functions, such as cell proliferation, apoptosis,
angiogenesis, carcinogenesis, metabolism, and cell motility [32–35].
Based on structural similarities and co-factor dependence the PKC
isoforms have been classiﬁed into three subfamilies [35–38]. The
classical PKCs (α, ßI, ßII, and γ) are Ca2+-dependent and are activated
by diacylglycerol (DAG) and phosphatidylserine (PS). The novel PKCs
(δ, ε, η, and θ) are Ca2+-independent and require DAG/PS for full
activation. The atypical PKCs (λ and ζ) require only PS for activation.
Among the PKC isoforms PKCε is known to be oncogenic which
promotes tumor growth and recurrence by increasing cell prolifera-
tion as well as by decreasing apoptosis [32–35,39]. Thus, we wanted
to examine whether PKCε plays a role as a downstream mediator in
the survival-promoting effects of 5-LOX in prostate cancer cells. We
observed that when prostate cancer cells are treated with MK591 to
induce apoptosis, there is a rapid and signiﬁcant loss of PKCε activity
in these cells, and both the reduction of PKCε activity and induction of
apoptosis are prevented by 5-oxoETE, a metabolite of 5-LOX.Moreover, we observed that 5-LOX inhibition-induced apoptosis is
prevented by chemical or peptide activators of PKCε. These novel
ﬁndings suggest that 5-LOX inhibition-induced apoptosis in prostate
cancer cells is mediated via down-regulation of PKCε. Since, prostate
cancer cells readily generate 5-HETE-series of eicosanoids from
arachidonic acid, our ﬁndings suggest that prostate cancer cells gain
survival advantage from arachidonic acid-rich Western diets
[9,10,12], by generating 5-LOX metabolites followed by downstream
signaling through the serine/threonine kinase, PKCε.
2. Materials and methods
2.1. Cell culture and reagents
LNCaP human prostate cancer cells were purchased from American
Type Culture Collection (Manassas, VA). Cells were grown in RPMI
medium 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% FBS
and antibiotics. Polyclonal antibodies against PKCε and PARPwere from
Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal anti-5-Lox was
purchased from BD Biosciences (Lexington, KY). Anti-beta-actin
antibody and ibuprofen were purchased from Sigma (St. Louis, MO).
5-OxoETE was purchased from Cayman Chemical (Ann Arbor, MI).
Lentiviral particles generating 5-LOX shRNA (small hairpin-RNA) were
bought from Santa Cruz Biotech (Santa Cruz, CA). ELISA kit to measure
PKCε activity was purchased from Cell Signaling Technology (Danvers,
MA). MK591 was obtained as a generous gift from Dr. Robert N. Young
(Merck-Frosst Centre for Therapeutic Research, Quebec, Canada).
2.2. Cell viability assay
LNCaP prostate cancer cells (~5000 per well) were plated
overnight in 96 well plates in complete growth medium (RPMI or
DMEM plus 10% FBS) and treated with varying doses of MK591. Plates
were incubated further for 72 h at 37 °C in the CO2 incubator. Cell
viability was measured by One Solution MTS/PES Cell Titer assay from
Promega (Madison, WI) as described before [9,12].
2.3. Eicosanoid measurement
LNCaP cells (1×106 per plate) were plated in 100 mm diameter
tissue culture plates in phenol red-free RPMI medium supplemented
with 10% FBS and allowed to grow for 48 h. The old mediumwas then
replaced with 5 ml fresh RPMI medium and treated with MK591 for
24 h. Cell culture media were harvested, centrifuged to clear cells and
debris, and then lipidswere extracted using Hypersep C18 solid-phase
extraction columns (Thermo Fisher). Samples were dried with gentle
nitrogen ﬂush and re-suspended in 40 μl methanol. Metabolites of
5-LOX weremeasured by liquid chromatography/ESImass-spectrometry
(LC/MS/MS) with a Micromass-Waters QuattroLC mass spectrometer
(Milford,MA)using 5(S)-HETE-d8 and5-oxoETE-d7 as internal standards
(Cayman Chemicals, Ann Arbor, MI) following methods published
recently by Maddipati et al. [40].
2.4. Annexin-V binding
Cells (~3×105) were plated in RPMI medium and allowed to grow
for 48 h. The spent culture mediumwas replaced with fresh 2 ml RPMI
medium and the cells were treatedwithMK591 or ibuprofen for 24 h at
37 °C. Then the cells in the plate were treated with FITC-labeled
annexin-V and propidium-iodide (PI) for 15 min in the dark using
Annexin V-Binding Detection Kit following a protocol supplied by the
manufacturer (BDBiosciences). Afterwashing, cellswere photographed
withaNikondigital camera attached toa LEICAﬂuorescencemicroscope
at 20×. Image acquisition and data processing were done with a Dell
computer attached to the microscope using SPOT-Advanced software.
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Cells were treated with MK591 for 24 h at 37 °C, harvested by
trypsinization, washed in PBS, and ﬁnally suspended in Annexin-V
binding buffer. Cells were stained with Annexin V and PI using
Annexin-V-Binding Detection assay kit from BD Biosciences and
apoptosis was quantitatively measured by ﬂow cytometry (Accuris,
Ann Arbor, MI).
2.5. Western blot
Cells (~3×105) were plated and allowed to grow for 48 h. The old
mediumwas then replaced with 2 ml fresh RPMI medium and the cells
were treated with inhibitors. After treatment, cells were harvested,
washed, and lysed in lysis buffer (50 mMHEPES, pH 7.4, 150 mMNaCl,
1 mM EDTA, 1 mM orthovanadate, 10 mM sodium pyrophosphate,
10 mMsodiumﬂuoride, 1%NP-40, and a cocktail of protease inhibitors).
Proteins were separated by 12% SDS-PAGE and transferred to
nitrocellulose membranes. Membranes were blocked with 5% nonfat-
milk solution and then blotted with appropriate primary antibody
followed by horseradish peroxidase-labeled secondary antibody. Bands
were visualized by enhanced chemiluminescence detection kit from
Pierce Biotech (Rockford, IL) and analyzed with a densitometer using
Kodak imaging software. Unless otherwisementioned, blots of proteins
of interest were analyzed in three separate experiments.
2.6. Cell fractionation
Cells were plated in 100 mm diameter tissue culture plates and
allowed to grow for 48 h. Then the cells were treated with MK591 for
varying periods of time. At the end of incubation, cells were washed
with PBS and the plasmamembrane fractions were isolated using a kit
following manufacturer's protocol (Biovision, Mountain View, CA).
Membrane fractions were stored at −80 °C and solubilized in lysis
buffer for analysis by Western blot.
2.7. Measurement of PKCε activity by immunoprecipitation-kinase
(IP-kinase) assay
Prostate cancer cells (~1×106) were plated in 100 mm diameter
plates and allowed to grow for 48 h. The old culture mediumwas then
replaced with fresh 5 ml RPMI medium and the cells were treated
with inhibitors or solvent vehicle (0.2% DMSO) for varying periods of
time up to 6 h. Then the cells were lysed in lysis buffer (50 mMHEPES,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM orthovanadate, 10 mM
sodium pyrophosphate, 10 mM sodium ﬂuoride) containing 0.4%
Triton-X100, 10% glycerol, and a cocktail of protease inhibitors.
Enzymatic activity of PKCε was measured by an ELISA method using
biotin-labeled peptide substrate (Cell Signaling Technology, Danvers,
MA). Brieﬂy, cell lysates were cleared by centrifugation at 12,000 ×g
for 10 min at 4 °C and the supernatants (~500 μg proteins) were used
for immunoprecipitation of PKCε using 4 μg anti-PKCε antibody. The
tubes were rotated overnight at 4 °C and the immune complexes were
precipitated using anti-rabbit IgG-coatedmagnetic beads (Invitrogen)
for 2 h at 4 °C. Then the beadswerewashed ﬁve timeswith lysis buffer
containing 0.1% Triton-X100 and ﬁnally suspended in 25 μl of 1×
kinase assay buffer. Enzymatic reactions in 50 μl were carried out for
15 min at room temperature (RT) using 10 μl of IP-slurry with beads,
and stopped with 50 μl of 50 mM EDTA. Aliquots of reaction mixtures
(25 μl) were placed into streptavidin-coated 8-well strips and
incubated for 60 min at RT. Wells were washed and phosphorylation
of biotinylated-peptide substrate (cAMP response element-binding
protein or CREB at Ser-133) was detected by speciﬁc anti-phospho-
serine primary antibody followed by secondary HRP-labeled anti-
rabbit antibody. After washing, color was developed using ABTS
(2,2′-azino-di (3-ethylbenzthiazoline-6-sulfonate) as substrate for15 min at RT. Absorbance was measured at 405 nm in a digital plate
reader (Bio-Tek Instruments).
2.8. Measurement of DNA degradation
Apoptosis was quantitatively measured by detecting degradation
of nuclear DNA to nucleosomal fragments by sandwich-ELISA. LNCaP
cells (~3×105) were plated in 60 mm dishes and allowed to grow for
48 h. Cells were then treated either with the experimental agents or
the solvent vehicle for varying periods of time up to 24 h. At the end of
incubation periods, cells were lysed and the degradation of chromatin-
DNA to nucleosomal fragments was measured by Cell Death
Detection ELISAplus kit from Roche (Indianapolis, IN) as described
before [12,13].
2.9. Statistical analysis
Signiﬁcance of the difference between values in treated and
untreated groups were calculated by two-tailed student's t-test using
GraphPad Instat Software. A p value of b0.05 was considered to be
statistically signiﬁcant.
3. Results
3.1. Inhibition of 5-LOX decreases viability of prostate cancer cells
We observed that MK591, a speciﬁc inhibitor of 5-LOX activity
[30,31], decreases viability of prostate cancer cells, which is
accompanied by a signiﬁcant inhibition in the production of 5-LOX
metabolites (Fig. 1A–C). Ibuprofen (an inhibitor of cyclooxygenase)
was used as negative control which did not affect viability of cells or
the production of 5-LOX metabolites. Decreased cell viability was also
observed when the cells were treated with lentiviral 5-LOX shRNA to
decrease level of 5-LOX expression, conﬁrming a role of 5-LOX in
prostate cancer cell survival (Fig. 1D–F). These experiments were
performed with LNCaP human prostate cancer cell line which
represents the most authentic prostate cancer cell line available
[41]. However, other human (PC3, DU145) as well as mouse (TRAMP-C1,
Myc-Cap) prostate cancer cell lines are also similarly affected when
treated with MK591 (Sarveswaran et al.; Manuscripts in preparation).
3.2. Inhibition of 5-LOX induces membrane lipid-asymmetry,
PARP-cleavage, and DNA-degradation in prostate cancer cells
Next we examined whether prostate cancer cells externalize
phosphatidylserine (a hall-mark of apoptotic cell death) when treated
with MK591. We observed that LNCaP cells show distinctly positive
binding with annexin-V when treated with MK591, suggesting
externalization of phosphatidylserine to the cell surface (Fig. 2A).
Annexin binding was also quantitatively measured by ﬂow cytometry
(Fig. 2B). Characteristic cleavage of PARP (poly-ADP ribose polymerase),
an indicator of caspase-mediated apoptosis, was observed to occur in a
dose-dependent manner (Fig. 2C). Further analysis revealed degradation
of nuclear-DNA to nucleosomal fragments which is an indicator of
advanced stage of apoptosis (Fig. 2D). Cells treated with ibuprofen in
parallel experiments, did not show any signs of apoptotic features,
suggesting that the effect of 5-LOX inhibition to induce apoptosis in
prostate cancer cells is selective.
3.3. Inhibition of 5-LOX decreases expression and membrane localization
of PKCε in prostate cancer cells
The mechanism how 5-LOX activity regulates prostate cancer cell
survival is an intriguing but unanswered question. Recently, we
reported that the 5-LOX inhibition-induced apoptosis in prostate
cancer cells occurs without inhibition of Akt, or ERK [29]. Thus, next
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apoptosis in a variety of cell types [32,38,39]. To investigate the
potential role of PKCε as a downstream mediator of the survival-
promoting effects of 5-LOX, we observed that treatment with MK591 or
5-LOX shRNA decreases expression of PKCε in prostate cancer cells
(Fig. 3A,B). We also observed that prostate cancer cells treated with
MK591showedarapiddecrease in themembrane localizationofPKCε in a
time-dependentmanner (Fig. 3C,D). Aminor decreasewas noticed in the
level of cytosolic PKCε in short-term (4–6 h) treatment (not shown).
3.4. Inhibition of 5-LOX down-regulates the enzymatic activity of PKCε in
prostate cancer cells
To explore the state of activity of PKCε in prostate cancer cells, we
observed that prostate cancer cells maintain catalytically active state
of PKCε under normal culture condition without any exogenous
treatment. We analyzed the enzymatic activity of PKCε after
immunoprecipitation, and further conﬁrmed PKCε activity using
speciﬁc peptide inhibitor of PKCε (KIE1-1) (Fig. 4A,B). Interestingly,
it was observed that treatment of cells with the 5-LOX inhibitor,
MK591, decreases the enzymatic activity of PKCε in a time-dependent
manner, suggesting that PKCε is regulated by 5-LOX activity in
prostate cancer cells (Fig. 4C). We also observed that phosphorylation
of the transcription factor Stat3 at serine-727, which has been
characterized to be a PKCε phosphorylation site [42], is decreased in
a dose and time-dependent manner (Fig. 4D,E).Fig. 2. Induction of apoptosis in prostate cancer cells by MK591. LNCaP cells (3×105) were p
replaced with 2 ml fresh RPMI medium and the cells were treated either with MK591 (8 μM)
DMSO). At the end of incubation period, cells in binding bufferwere treatedwith FITC-labeled a
(B), cells were treated with 8 μMMK591 for 24 h and apoptosis was quantitatively measured d
lysed and cleavage of PARP was detected by Western blot. In (D), degradation of DNA was d
(**pb0.005, n=4).3.5. 5-OxoETE, a metabolite of 5-LOX, prevents MK591-induced
inhibition of PKCε and induction of apoptosis
Inhibition of PKCε activity in prostate cancer cells treated with
MK591 suggested that 5-LOX activity regulates PKCε. However, if
5-LOX activity regulates PKCε, then it is expected that metabolic
products of 5-LOX should reverse the inhibitory effects of MK591
treatment. Thus, we treated prostate cancer cells with 5-oxoETE, a
metabolic product of 5-LOX, before treating them with MK591 and
observed that 5-oxoETE effectively prevents MK591-induced inhi-
bition of PKCε activity (Fig. 5A). In a separate set of experiments,
we observed that MK591 treatment-induced apoptosis in prostate
cancer cells is prevented by 5-oxoETE, conﬁrming that PKCε is under
regulation of 5-LOX activity in prostate cancer cells (Fig. 5B).
3.6. MK591 is not a direct inhibitor of PKCε, and MK591-induced
apoptosis in prostate cancer cells is prevented by activators of PKCε
We wanted to address the question whether MK591 directly
inhibits the enzymatic activity of pure PKCε through an off-target
effect in addition to its authentic inhibitory effects on 5-LOX activity.
We observed that MK591 does not inhibit PKCε activity when directly
added to the assay mixture containing immunoprecipitated PKCε
from LNCaP cells (Fig. 6A). Next we asked the question whether
activation of PKCε by other means can prevent 5-LOX inhibition-
induced apoptosis in prostate cancer cells, because if inhibition oflated in 60 mm diameter plates and allowed to grow for 48 h. Then the old medium was
or ibuprofen (10 μM) at 37 °C for 24 h. Control cells were treated with vehicle only (0.2%
nnexin-V and propidium iodide (PI), andwere observed undermicroscope at 200× (A). In
etecting annexin-V binding by ﬂow cytometry. In (C), at the end of incubation, cells were
etected by ELISA. Results are shown as mean values of each data point±standard error
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that activators of PKCε should overcome the apoptosis-inducing
effects of 5-LOX inhibition. We addressed this question by treating
prostate cancer cells with diazoxide, a chemical activator of PKCε [43],
before treating them with 5-LOX inhibitor and observed that
diazoxide effectively prevents 5-LOX inhibition-induced apoptosis
(Fig. 6B). We also observed that pretreatment of cells with KAE1-1, a
TAT-labeled speciﬁc octa-peptide activator of PKCε [44] is effective in
preventing MK591-induced apoptosis. Altogether, these ﬁndings
suggest that inhibition of 5-LOX induces apoptosis in prostate cancer
cells via inactivation of PKCε, and that PKCε is a mediator of survival
signals downstream of 5-LOX metabolites.
4. Discussion
Our observation of a dramatic reduction in the viability of prostate
cancer cells byMK591, or by 5-LOX-speciﬁc shRNA, demonstrates that
prostate cancer cells depend on 5-LOX activity for survival (Fig. 1). We
also observed that MK591 treatment-induced cell death is accompa-
nied by standard apoptotic features such as externalization of
phosphatidylserine, cleavage of PARP, and degradation of chromatin-
DNA to nucleosomal fragments (Fig. 2). It is interesting to note thatA
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SDS-PAGE and phosphorylation of Stat3 at serine-727 was detected by Western blot. A repunder normal health conditionsmost normal parenchyma body cells do
not express 5-LOX. However, over-expression of 5-LOX has been
implicated in inﬂammatory diseases, such as asthma, arthritis, psoriasis,
and a variety of cancers such as cancer of the prostate, lung, pancreas,
and brain [14–19]. Thus, agents that speciﬁcally block the activity of 5-
LOXmay turn out to be attractive tools to treat these diseases. MK591 is
a speciﬁc synthetic inhibitor of 5-LOX and is currently under
development for the treatment of asthma [30,31]. It blocks synthesis
of leukotrienes by inhibiting 5-LOX activity via binding with its
activating protein, FLAP, but it does not inhibit cyclooxygenase,
epoxygenase, or 12-lipoxygenase activities. Our observation of the
prevention of MK591-induced apoptosis in prostate cancer cells by
exogenousmetabolites of 5-Lox conﬁrms that induction of apoptosis by
MK591 occurs via inhibition of 5-LOX activity. Recently, we observed
that MK591 strongly inhibits the growth of prostate tumors in nude
mice xenografts (Sarveswaran et al., Manuscript in preparation). Thus,
MK591 is emerging as a novel, targeted agent for prostate cancer
therapy.
Though 5-LOX activity plays an essential role in the survival of
prostate cancer cells, downstream signaling mechanisms underlying
regulation of prostate cancer cell survival by 5-LOX are not
characterized yet. We addressed this question by examining theC
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P-kinase assay as described in the “Methods” section. No Enz (=no enzyme added) and
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an values±standard error (n=4). In (C), LNCaP cells were treated as indicated and the
d E), LNCaP cells (3×105) were plated in 60 mm diameter plates as in Fig. 3A above, and
vehicle only (0.2% DMSO). Cell lysate proteins (100 μg per lane) were separated in 12%
resentative of two experiments with similar results is shown here.
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play important roles in cell-viability. The PI3K-Akt axis is a well
known pro-survival mechanism and plays an important role in the
viability of many types of cancer cells [21–25]. Thus, this pathway has
emerged as a valid target for anti-cancer drug development, and a
series of compounds have been identiﬁed/generated for mechanistic
studies as well as for clinical testing. The ERK pathway is also known
to promote growth and survival of a variety of cell types including
cancer cells [26–28]. However, we recently reported that MK591-
induced apoptosis in prostate cancer cells occurs without inhibition of
Akt, and an increase rather than decrease in the activation of ERK1/2
[29]. These ﬁndings indicated that the 5-LOX activity feeds a
mechanism which is independent of Akt and ERK, and suggested
that prostate cancer cells are equipped with additional survival
mechanisms which may help them to bypass chemotherapies that are
directed against Akt and ERK, two well-characterized anti-cancer
molecular targets. Existence of an Akt-independent survival mecha-
nism in LNCaP prostate cancer cells was reported previously using a
panel of survival/growth factors in the presence or absence of
inhibitors of PI3K-Akt [45]. However, details about the identity of
possible kinase(s) behind the Akt-independent mechanism of
prostate cancer cell survival were not characterized. Thus, we wanted
to investigate the involvement of PKCε as a potential mechanism ofA
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Fig. 5. Prevention of MK591-induced inhibition of PKCε and induction of apoptosis by
5-oxoETE. In (A), LNCaP cells were plated as in Fig. 4A and treated with 8 μM MK591
with or without 10 μM 5-oxoETE for 6 h. Ibuprofen (10 μM) was used in parallel as
negative control. Control cells were treated with vehicle only (0.2% DMSO) for 6 h. Then
the cells were lysed and the enzymatic activity of PKCε was determined by IP-kinase
assay. Results represent mean value of each data point±standard error (*pb0.05,
**pb0.005, n=3). In (B), cells were plated and treated with MK591 as in Fig. 2D with or
without the addition of 5-oxoETE for 24 h. At the end of incubation period, apoptosis
was measured by ELISA. Results represent mean values of each data point±standard
error (**pb0.005, n=3).prostate cancer cell survival regulated by 5-LOX activity, because this
kinase is also well known to promote survival and growth of a variety
of cells including cancer cells [32,33].
A characteristic feature of prostate cancer cells appears to be
maintenance of a continuous activation of PKCε. This feature was
previously demonstrated in prostate tumor tissues by immunohisto-
chemistry showing membrane localization of PKCε, and also by its
colocalization, phosphorylation and activation of the transcription
factor Stat3 [42]. In this study, we observed that the level of PKCε is
down-regulated when prostate cancer cells are treated with MK591
or shRNA against 5-LOX (Fig. 3A,B). We also found that under normal
culture condition a substantial amount of PKCε protein in prostate
cancer cells is membrane-localized which corresponds to its active
state, and that treatment with MK591 decreases membrane localiza-
tion of PKCε in a time-dependent manner (Fig. 3C,D). Only a minor
decrease was noticed in the level of cytosolic PKCε, suggesting that
MK591 mainly induces a decrease in membrane-localization rather
than degradation of PKCε in short-term treatment (not shown).B
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Fig. 6. Direct effect ofMK591 on PKCε, and prevention of 5-Lox inhibition-induced apoptosis
in prostate cancer cells by activators of PKCε. In (A), PKCε was immunoprecipitated from
2×106 exponentially growing LNCaP cells without treatment. Then, equal aliquots of the
isolated PKCε enzymes were treated with the agents (MK591=10 μM; KIE1-1=50 μM) for
10min at RT beforemeasuring the kinase activity. Results are shown asmean values of each
data point±standard error (**pb0.005, n=3). In (B), LNCaP cells (3×105)were plated as in
Fig. 2D and the cells were treatedwithMK591 (8 μM)with orwithout the activators of PKCε
as indicated for 24 h. Control cells were treatedwith solvent only (0.2% DMSO). At the end of
incubation period, apoptosis was measured by Cell Death ELISA. Data presented as mean
values±standard error (**pb0.005, n=4).
2116 S. Sarveswaran et al. / Biochimica et Biophysica Acta 1813 (2011) 2108–2117Moreover, the enzymatic (IP-kinase) assay conﬁrmed that prostate
cancer cells maintain signiﬁcant levels of PKCε activity under normal
culture conditions, and MK591 treatment decreases the catalytic
activity of PKCε in a time-dependent manner (Fig. 4C). Inhibition of
the activity PKCε was also reﬂected by decreased phosphorylation of
the transcription factor Stat3 at serne-727 which is a well known
substrate of PKCε (Fig. 4D,E). It is interesting to note that both the
MK591 treatment-induced inhibition of PKCε activity, and induction
of apoptosis are inhibited by 5-LOXmetabolites, which suggest that 5-
LOX activity regulates survival of prostate cancer cells via PKCε
(Fig. 5A,B). To rule out the possibility of any off-target effect of MK591
on PKCε activity, we tested direct effect of MK591 on isolated PKCε
from LNCaP cells, which showed that MK591 does not affect the
activity of pure PKCε enzyme by direct interaction (Fig. 6A). Finally,
prevention of 5-LOX inhibition-induced apoptosis by chemical as well
as speciﬁc peptide-activators of PKCε supports the concept that the
survival-promoting effects of 5-LOX in prostate cancer cells are
mediated, at least partially, via signaling through a PKCε-dependent
mechanism (Fig. 6B).
Based on the report of Aziz et al. [42], and our currentwork, it appears
that PKCε is continuously active in prostate tumor tissues and in prostate
cancer cells in culture. However, how PKCεmaintains continuous activity
in prostate cancer cells is an intriguing but unanswered question. A
generally accepted paradigm for the activation of PKCε involves two
sequential steps. In theﬁrst step, PKCε gets phosphorylated at a threonine
residue at the activation loopbyphospholipid-dependent kinase1 (PDK1)
which triggers autophosphorylation on a threonine residue in the turn
motif and serine residues in the hydrophobicmotif [37]. In un-stimulated
cells, the mature triple-phosphorylated form of PKCε stays in the cytosol
where the pseudo-substrate region blocks its active site and the enzyme
remains inanauto-inhibited state. Subsequent activationof PKCεdepends
onbindingwith a lipid secondmessenger, suchasdiacylglycerol (DAG), in
the membrane which allows PKCε to become active and phosphorylate
target substrates. However, upstream signals that may feed PKCε for its
continuous activity in prostate cancer cells are yet to be characterized.
Earlier, we reported that prostate cancer cells continuously generate
5-LOX metabolites from arachidonic acid [9,12], which may ideally
provide the signals needed for continuous action of PKCε. However, the
mechanism how 5-LOXmetabolites may activate PKCε in prostate cancer
cells is still uncharacterized. It was observed that prostate cancer cells
express both the mRNA and protein of OXER1 [[46], and Sarveswaran et
al.; Unpublished observations], a G protein-coupled receptor (GPCR), for
which the 5-LOX metabolites 5-oxoETE and to a lesser extent 5(S)-HETE
serve as ligands [47,48]. These ﬁndings led us to hypothesize that 5-LOX
metabolitesmay provide survival signaling to prostate cancer cells via the
GPCR, OXER1, and consequent production of diacylglycerol (DAG) to
activate PKCε. Further work is undergoing to test this hypothesis.
Inhibition of PKCε in prostate cancer cells by treatment with the 5-
LOX inhibitor MK591, its reversal by 5-oxoETE, and prevention of
MK591-induced apoptosis by chemical as well as peptide activators of
PKCε indicate that 5-LOX inhibition-induced apoptosis in prostate
cancer cells occur via inhibition of PKCε, and suggest that the survival-
promoting effects of arachidonate 5-LOX in prostate cancer cells are
mediated via PKCε. Thus, a fundamental mechanism of cell survival
has been uncovered which is continuously active in prostate cancer
cells. Regulation of PKCε activity in prostate cancer cells by inhibitors
andmetabolites of 5-LOX opens up a new avenue to explore activation
mechanisms of PKCε in prostate and other types of cancer cells. PKCε
is a transforming oncogene which is well characterized to promote
cell survival by regulating Bcl-2 family members, such as Bcl-2, Bad
and Bax, and to increase resistance to apoptosis-inducing agents
[38,39,49–52]. Moreover, a recent gene-ablation study revealed that
PKCε plays an important role in prostate cancer development and
metastasis in transgenic mice [53]. Cancer-speciﬁc expression of 5-
LOX in prostate epithelial cells together with a critical role of 5-LOX in
the survival of prostate cancer cells suggests for a pivotal and possiblyan indispensable role of 5-LOX in the development and progression of
prostate cancer. Thus, 5-LOX is emerging as a promising, novel target
for prostate cancer therapy. Since arachidonic acid is a common fatty
acid in “Western-diets” (where prostate cancer is also more
common), and 5-LOX is highly expressed in prostate cancer cells,
our present ﬁndings suggest that metabolism of arachidonic acid via
5-LOX may greatly contribute to the pathobiology of prostate cancer
by enhancing the protean effects of PKCε and its downstream
oncogenic signaling.
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